Insights and advances in CRISPR, cell line development and drug discovery
Solentim, a global leader in cell line development instrumentation, is pleased to announce it will be exhibiting at ELRIG’s second CRISPR in Drug Discoveryconference, 4-5 March 2020 at the Babraham Institute in Cambridge.
Focusing on the applications of genome engineering throughout the drug discovery pipeline, attendees will gain unique insights into the industry ‘From Targets to Therapeutics’. The meeting will provide a current perspective on the power of new technologies to identify novel drug targets through large scale CRISPR-based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing. The event will bring together the research community working in genome engineering with interests in developing and applying the technology for pharmaceutical research.
Mark Truesdale, Chief Marketing Officer, Solentim, commented: “We are excited to return to this meeting after a successful and insightful event in 2019. This is an excellent opportunity to catch up with existing customers, connect with new collaborators, and broaden the awareness of our tools and applications within the European cell line development community.”
Solentim can be found at Booth #24 throughout the conference.